NSE - Delayed Quote INR

NATCO Pharma Limited (NATCOPHARM.NS)

Compare
1,392.00 +29.70 (+2.18%)
At close: 3:29:59 PM GMT+5:30
Loading Chart for NATCOPHARM.NS
DELL
  • Previous Close 1,362.30
  • Open 1,365.50
  • Bid --
  • Ask --
  • Day's Range 1,364.65 - 1,408.45
  • 52 Week Range 800.55 - 1,639.00
  • Volume 331,244
  • Avg. Volume 667,680
  • Market Cap (intraday) 249.329B
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 12.82
  • EPS (TTM) 108.58
  • Earnings Date Feb 12, 2025 - Feb 17, 2025
  • Forward Dividend & Yield 5.75 (0.41%)
  • Ex-Dividend Date Nov 27, 2024
  • 1y Target Est 1,337.27

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

www.natcopharma.co.in

4,016

Full Time Employees

March 31

Fiscal Year Ends

Recent News: NATCOPHARM.NS

View More

Performance Overview: NATCOPHARM.NS

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NATCOPHARM.NS
72.30%
S&P BSE SENSEX
8.94%

1-Year Return

NATCOPHARM.NS
73.80%
S&P BSE SENSEX
10.32%

3-Year Return

NATCOPHARM.NS
68.57%
S&P BSE SENSEX
37.77%

5-Year Return

NATCOPHARM.NS
152.69%
S&P BSE SENSEX
91.19%

Compare To: NATCOPHARM.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NATCOPHARM.NS

View More

Valuation Measures

As of 12/26/2024
  • Market Cap

    244.01B

  • Enterprise Value

    221.46B

  • Trailing P/E

    12.54

  • Forward P/E

    16.86

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.37

  • Price/Book (mrq)

    3.41

  • Enterprise Value/Revenue

    4.88

  • Enterprise Value/EBITDA

    8.66

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    42.61%

  • Return on Assets (ttm)

    18.89%

  • Return on Equity (ttm)

    31.23%

  • Revenue (ttm)

    45.64B

  • Net Income Avi to Common (ttm)

    19.45B

  • Diluted EPS (ttm)

    108.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.63B

  • Total Debt/Equity (mrq)

    2.91%

  • Levered Free Cash Flow (ttm)

    8.78B

Research Analysis: NATCOPHARM.NS

View More

People Also Watch